Stocktoria
Insight Molecular Diagnostics Inc. IMDX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2015-12-30
Insight Molecular Diagnostics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 | $2.2M |
| Gross profit | $2.3M | $740,000 | $413,000 | -$18,000 | $1.4M |
| R&D expense | $15.9M | $9.8M | $9.3M | $7.3M | $5.0M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$53.7M |
| Income tax | $0 | $0 | $0 | — | -$9.3M |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M | -$64.1M |
| EPS (diluted) | $-1.65 | $-4.66 | $-3.75 | $-13.25 | — |
| Operating cash flow | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M | -$38.2M |
| Cash & equivalents | $11.6M | $8.6M | $9.4M | $20.0M | $32.9M |
| Inventory | $446,000 | $410,000 | — | — | — |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M |
| Shareholders' equity | -$31.5M | -$12.3M | $20.5M | $34.3M | $65.2M |
Source: SEC EDGAR filings · CIK 0001642380 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.